Filing Flows › Nurix Therapeutics (NRIX) › Q2 FY26 › vs Q2 FY25
Nurix Therapeutics (NRIX) Q2 FY26 vs Q2 FY25 (year over year)
Nurix Therapeutics's revenue fell $35.0M (-79%) from $44.1M in Q2 FY25 to $9.0M in Q2 FY26.
Nurix Therapeutics, Q2 FY26: revenue $9.0M (-80% year over year), net loss $89.5M, operating cash flow −$96.6M. The chart draws each line against Q2 FY25, the increases inside each band.
Every line
| Line | Q2 FY26 | Q2 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $9.0M | $44.1M | −$35.0M | -79% |
| Other income, net | $4.4M | $5.6M | −$1.2M | -22% |
| Income tax benefit | $271K | −$760K | $1.0M | — |
| Net loss | $89.5M | $43.5M | $46.1M | +106% |
| Costs & expenses | $103M | $93.1M | $10.1M | +11% |
| Operating costs | $103M | $92.4M | $10.9M | +12% |
| Research & development | $87.7M | $78.1M | $9.6M | +12% |
| General & admin | $15.6M | $14.3M | $1.3M | +9% |
| Operating cash sources | $110M | $75.8M | $34.4M | +45% |
| Depreciation & amortization | $2.3M | $2.2M | $13K | +0.6% |
| Share-based compensation | $11.4M | $10.4M | $1.0M | +10% |
| Cash used in operations | $96.6M | $63.2M | $33.4M | +53% |
| Net loss absorbed | $89.5M | $43.5M | $46.1M | +106% |
| Working capital & other | $20.7M | $32.3M | −$11.6M | -36% |
Questions
How much did Nurix Therapeutics's revenue grow year over year in Q2 FY26?
Nurix Therapeutics's revenue fell $35.0M (-79%) from $44.1M in Q2 FY25 to $9.0M in Q2 FY26.